Your browser doesn't support javascript.
loading
Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the In Vitro Potency of Direct-Acting Antiviral Agents.
McPhee, Fiona; Ueland, Joseph; Vellucci, Vincent; Bowden, Scott; Sievert, William; Zhou, Nannan.
Afiliación
  • McPhee F; Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA fiona.mcphee@bms.com.
  • Ueland J; Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.
  • Vellucci V; Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.
  • Bowden S; Victorian Infectious Diseases Reference Laboratory, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Sievert W; Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia.
  • Zhou N; Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.
Article en En | MEDLINE | ID: mdl-30718256

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antivirales / Polimorfismo Genético / Hepatitis C / Proteínas no Estructurales Virales / Hepacivirus Límite: Humans Idioma: En Revista: Antimicrob Agents Chemother Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antivirales / Polimorfismo Genético / Hepatitis C / Proteínas no Estructurales Virales / Hepacivirus Límite: Humans Idioma: En Revista: Antimicrob Agents Chemother Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos